Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Other Non Operating Income: 2016-2025

Historic Other Non Operating Income for Tg Therapeutics (TGTX) over the last 4 years, with Sep 2025 value amounting to $3.3 million.

  • Tg Therapeutics' Other Non Operating Income rose 22.47% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.2 million, marking a year-over-year increase of 98.86%. This contributed to the annual value of $7.7 million for FY2024, which is 52.52% up from last year.
  • According to the latest figures from Q3 2025, Tg Therapeutics' Other Non Operating Income is $3.3 million, which was up 16.90% from $2.8 million recorded in Q2 2025.
  • Tg Therapeutics' 5-year Other Non Operating Income high stood at $3.6 million for Q1 2025, and its period low was $604,000 during Q1 2023.
  • In the last 3 years, Tg Therapeutics' Other Non Operating Income had a median value of $2.6 million in 2024 and averaged $2.0 million.
  • As far as peak fluctuations go, Tg Therapeutics' Other Non Operating Income tumbled by 53.89% in 2023, and later skyrocketed by 309.43% in 2025.
  • Tg Therapeutics' Other Non Operating Income (Quarterly) stood at $1.9 million in 2022, then crashed by 53.89% to $890,000 in 2023, then skyrocketed by 188.20% to $2.6 million in 2024, then grew by 22.47% to $3.3 million in 2025.
  • Its Other Non Operating Income stands at $3.3 million for Q3 2025, versus $2.8 million for Q2 2025 and $3.6 million for Q1 2025.